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Abstract
Background Dopamine agonists disrupt prepulse inhibition
(PPI) of startle in male rodents. In humans, this is observed
only in some studies. We reported that PPI was disrupted
by D-amphetamine in men, but only among those with high
basal PPI levels. Here, amphetamine effects on PPI were
tested in normal women and female rats.
Materials and methods Acoustic startle and PPI were tested
in normal women after placebo or 20 mg amphetamine, in a
double-blind, crossover design, and in female rats after
vehicle or 4.5 mg/kg amphetamine. Rats were from
Sprague–Dawley (SD) and Long Evans (LE) strains that
differ significantly in gene expression in PPI-regulatory
circuitry, including levels of nucleus accumbens (NAC)
catechol-O-methyl transferase (COMT) mRNA.
Results Amphetamine was bioactive in humans based on
quantitative autonomic and self-rating measures, but did not
significantly change startle magnitude or PPI across all
subjects. Amphetamine’s effects on PPI in women corre-
lated significantly (p<0.0008) with placebo PPI levels
(reducing PPI only in women whose basal PPI levels
exceeded the sample median) and with measures of novelty
and sensation seeking. Amphetamine decreased PPI in SD
rats that have relatively low NAC COMT gene expression
and increased PPI in LE rats that have relatively high NAC
COMT gene expression.
Conclusion The dopaminergic regulation of PPI in humans
is related to basal levels of sensorimotor gating and to
specific personality traits in normal men and women. In
rats, the effects of amphetamine on PPI differ significantly
in strains with low vs. high NAC COMT expression.
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Introduction
Prepulse inhibition (PPI) is an operational measure of
sensorimotor gating, in which a startle response to an
intense stimulus is automatically suppressed by a weak lead
stimulus (Graham 1975). In humans, PPI is typically
assessed using electromyographic measures of the blink
response, while in rodents, PPI is typically assessed based
on quantification of whole body startle. PPI deficits are
found in several neuropsychiatric disorders (Braff et al.
1978; cf. Braff et al. 2001), and the biology of these deficits
has been the focus of intense study in humans and animal
models. Findings related to the neural regulation of PPI
suggest both similarities and differences across species. For
example, while the indirect DA agonist amphetamine
(AMPH) generally disrupts PPI in male rodents via its
dopamine-releasing effects in the nucleus accumbens
(NAC; Swerdlow et al. 1990; Zhang et al. 2000), it was
reported to reduce PPI only in specific subgroups of
humans, distinguished by smoking history or personality
features (Kumari et al. 1998; Hutchison and Swift 1999).
We failed to detect significant PPI-disruptive effects of
20 mg AMPH in normal men, using stimuli limited to a
100-ms prepulse interval, but subsequently detected PPI-
disruptive effects of this same dose of AMPH in normal
men, using a paradigm that included very short (10–20 ms)
prepulse intervals (Swerdlow et al. 2003b). However, even
in this sample, it was determined that the PPI-disruptive
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effects of AMPH largely reflected its impact on men with
the highest basal levels of PPI. More recently, Bitsios et al.
(2005) reported similar findings with other DA agonists:
both pergolide and amantadine reduced PPI among men
with basal PPI levels above the median of the normal
distribution, and actually increased PPI among men with
basal levels below the median of this distribution. Thus, the
emerging model for the DAergic regulation of PPI in
humans is that it differs across individuals in a rate-
dependent fashion. If this were simply a matter of PPI
“range” or a “regression to the mean”, then long prepulse
intervals (which evoke higher levels of PPI) would be more
sensitive to AMPH, compared to short prepulse intervals
(which evoke lower levels of PPI); if anything, the opposite
appears to be the case (Swerdlow et al. 2003b).
Normal personality traits, and presumably their underly-
ing neurobiology, also appear to be associated with differ-
ences in PPI drug sensitivity. Both the ability of AMPH to
reduce PPI, and the ability of antipsychotics to increase
PPI, appear to be enhanced among normal individuals with
high scores on temperament measures of novelty seeking
(Hutchison et al. 1999; Swerdlow et al. 2006). While it
might seem far-fetched to propose a biological relationship
between the neurochemical regulation of reflex modifica-
tion and a personality dimension, it has long been known
that psychophysiological measures ranging from auditory
and visual evoked potentials to PPI are consistently and
strongly linked to personality subtypes (e.g., Hegerl et al.
1989; Zuckerman 1990; Stenberg et al. 1988; Lukas 1987;
Juckel et al. 1995; Swerdlow et al. 1995). Perhaps most
importantly, high levels of novelty seeking in women are
associated with specific DA-linked genetic polymorphisms,
including the Met/Met genotype of the COMT Val158Met
polymorphism, conveying low activity to the enzyme
catechol-O-methyl transferase (Golimbet et al. 2007). This
Met/Met genotype yields COMT with significantly lower
activity than its Val/Val counterpart, which might lead to a
slower degradation of dopamine after presynaptic release.
In previous studies with male rats, we reported that the PPI-
disruptive effects of AMPH were significantly greater in
Sprague–Dawley (SD) rats than in Long Evans (LE) rats
(Swerdlow et al. 2003c), and that COMT gene expression
in the NAC is significantly lower (p<10−17) in SD vs. LE
rats (Shilling et al. 2008). Conceivably, low levels of
regional COMT gene expression might result in low levels
of enzymatic activity, analogous to the low activity
associated with the Met/Met allele most prominent among
high novelty seeking individuals.
All of the data reporting “rate-dependent” DA agonist
effects on PPI come from studies in men, and the present
study was designed to examine this issue in women. PPI is
sexually dimorphic: levels of uninstructed PPI (i.e., without
attention directed to the prepulse or pulse) are generally higher
in normal men compared to normal women (Swerdlow et al.
1993). PPI levels in women also appear to be sensitive to
hormonal regulation, as they shift across the menstrual cycle
(Swerdlow et al. 1997; Jovanovic et al. 2004) and during
pregnancy (Kask et al. 2008). Given the apparent sex
differences in the neural control of PPI, it would not be
reasonable to assume that patterns of PPI AMPH sensitivity
in women would reproduce those in men. We now report the
effects of AMPH (20 mg) on PPI in normal women, in
relationship to both baseline (placebo) levels of PPI, and
normal personality dimensions. These findings were then
extended to female rats from strains that differ significantly
in levels of COMT gene expression in the NAC.
Materials and methods
Human testing
The methods used in these studies were very similar to
those used in studies described in recent reports (Swerdlow
et al. 2003b), were approved by the UCSD Human Subjects
Institutional Review Board, and were approved and
supported by the National Institute of Mental Health.
Twenty R handed women (Table 1) completed testing; the
study involved phone contact and three laboratory visits.
Phone screening procedures were identical to those de-
scribed in previous reports from our group (Swerdlow et al.
2002, 2003b).
After passing a telephone interview, subjects came to the
laboratory within 72 h of menses onset. During a screening
examination, the senior investigator (NRS) informed sub-
jects of the potential risks and benefits of the study.
Subjects read and signed a consent for study participation,
underwent a physical examination and electrocardiogram to
rule out exclusionary medical conditions, and completed a
urine toxicology test with exclusion for any drug, and a
Table 1 Subject characteristics
Age (mean (range), years) 25.2 (18–32)
Weight (mean (range), kg) 61.7 (47.6–90.3)
Dose AMPH (mean (range), mg/kg) 0.32 (0.22–0.42)
Daily caffeine intake (mean (range), mg) 126.1 (0.0–768.0)
Personality scale scores (mean (range))
TPQ
Novelty seeking 15 (8–23)
Harm avoidance 9 (0–18)
Reward dependence 20 (9–27)
SSS
Total score 18 (7–30)
EPQ
Total score 20 (15–26)
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pregnancy test. Audiometry confirmed hearing threshold
<40 dB(A) at 1,000 Hz. Subjects also completed a limited
test of the acoustic startle reflex to screen for a minimum
eyeblink startle magnitude of 50 units (1.22 μV/unit) using
118 dB(A), 40 ms noise pulses; seven subjects were
excluded for failing to meet this criteria.
Subjects completed the following questionnaires: (1) the
Tridimensional Personality Questionnaire (TPQ; Cloninger
1987) to assess the relationship between novelty seeking
scores (NS) and sensitivity to the effects of AMPH on PPI,
based on reports that high NS individuals are most sensitive
to the PPI-disruptive effects of AMPH (Hutchison et al.
1999) and the PPI-enhancing effects of antipsychotics
(Swerdlow et al. 2006); (2) the Sensation Seeking Scale
(Zuckerman et al. 1972), based on reported increased
sensitivity to AMPH in individuals scoring high on this
measure (Hutchison et al. 1999); and (3) the Eysenck
Personality Questionnaire (EPQ; Eysenck and Eysenck
1994). Subjects who passed screening criteria were tested
6–8 days later, and retested 28–30 days after their first
experimental session, at the corresponding date in their next
menstrual cycle (i.e., approximately the same number of
days from menses onset). This schedule was designed to
ensure, to the degree possible, that PPI testing with AMPH
and placebo occurred under relatively comparable hormon-
al states—and thus was not confounded or made more
variable by hormonal differences—and this was confirmed
by measurements of plasma estradiol on both testing days
(see below). Testing was double-blind, and drug order was
randomized.
On test days, subjects arrived at 0830, ate a standardized
breakfast, had a venopuncture for estradiol levels, and D-
amphetamine (20 mg) or placebo was administered at 0930.
Startle testing began 60 min after pill administration. Heart
rate and blood pressure were determined (sitting position,
brachial cuff), and subjects completed a symptom rating
scale every 30–45 min, the first one before pill ingestion.
Symptom rating visual analog scales (VAS) were designed
to assess general somatic and psychological symptoms and
level of consciousness (modified from Norris 1971; Bond
and Lader 1974; Bunney et al. 1999). Subjects made a
single, vertical mark representing their current state along
on a 100-mm line (0 mm represents “not true” and 100 mm
represents “true”). Ratings assessed several states: “happy”,
“queasy”, “dizzy”, “drowsy”, and perceptual sensitivity.
Details of these rating scales are found in Swerdlow et al.
(2002) and included prompts such as “Normal sounds seem
unusually intense or loud”.
For startle testing, subjects sat upright and were directed
to look straight ahead, and to stay awake. Two miniature
Ag/AgCl electrodes were positioned below and to the outer
canthus of each eye over orbicularis oculi; ground electrode
was positioned behind the L ear (R<10 kΩ). EMG activity
was band-pass-filtered (1–1,000 Hz) and 60 Hz notch-
filtered, digitized, and 250 1 ms readings were recorded
starting at startle stimulus onset. Acoustic startle stimuli were
delivered by Telephonics (TDH-39-P, Maico) headphones. A
background 70 dB(A) white noise was continuous through-
out the session. Test sessions began with a 3-min acclimation
period; during this period, the number of spontaneous
eyeblinks were counted by a remote observer using a
RadioShack security camera system (model 49-2513; inter-
observer R=0.97). This was followed by 42 trials with six
conditions repeated in pseudorandom order: a 118-dB(A)
40 ms noise burst alone (pulse alone), and the same 118 dB
(A) 40 ms noise burst preceded 10, 20, 30, 60, or 120 ms by
a prepulse (5 ms burst) 16 dB over background. A variable
inter-trial interval averaged 20 s (15–25 s). The test session
was structured identically to that described in our previous
studies of AMPH effects on PPI in men (Swerdlow et al.
2003b). On completion of this startle test, additional
autonomic and subjective rating measurements were
obtained, as were additional “pilot” psychophysiological
measures, including a visual latent inhibition task. Data from
these subsequent tests are not included in this analysis.
The primary reasons for disqualification were that
subjects had low screening startle magnitude (n=7),
withdrew from testing prior to the second test day (n=6)
or SCID-based diagnosis (n=6); others included positive
urine toxicology (n=4) and medical exclusion (n=2).
PPI was defined as (100 − [100 × magnitude on prepulse
trial/magnitude on pulse alone trial]). Baseline PPI was
normally distributed (mean (SD) % across all intervals=
9.46 (20.32); median=14.18; skewness=−0.58; kurtosis=
−0.05). Startle magnitude and PPI were analyzed with
mixed-design ANOVAs, with trial type and drug dose as
within-subject factors. No consistent drug interactions were
noted with eye side (left vs. right), and thus the main effects
of eye side and interactions are not reported. VAS ratings
were treated as continuous variables and were analyzed
with mixed-design ANOVAs. Specific post hoc compar-
isons were made with one-factor ANOVAs or the Fisher’s
protected least significant difference test. Alpha was 0.05.
In most cases, post hoc comparisons were limited to tests of
specific a priori hypotheses (e.g., that DA agonist effects on
PPI would be rate-dependent) or planned comparisons (e.g.,
relationship of PPI AMPH sensitivity to personality
measures or estradiol levels).
Rodent testing
The methods used in this study were in accordance with the
National Institute of Health Guide for the Care and Use of
Laboratory Animals (NIH Publications No. 80-23) and
approved by the UCSD Animal Subjects Committee
(protocol #S01221). Adult female SD (n=10) and LE rats
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(225–250 g; Harlan Laboratories, San Diego, CA, USA)
were housed in groups of two to three animals per cage and
maintained on a reversed light/dark schedule with water
and food available ad libitum. Rats were handled within
2 days of arrival. Testing occurred during the dark phase. D-
amphetamine sulfate (AMPH) was dissolved in saline
vehicle and administered subcutaneously in doses of 0 or
4.5 mg/kg (as in Swerdlow et al. 2003c). Startle chambers
(San Diego Instruments, San Diego, CA, USA) were
housed in a sound-attenuated room and consisted of a
Plexiglas cylinder 8.2 cm in diameter resting on a 12.5×
25.5-cm Plexiglas frame within a ventilated enclosure.
Noise bursts were presented via a speaker mounted 24 cm
above the cylinder. A piezoelectric accelerometer mounted
below the Plexiglas frame detected and transduced motion
from within the cylinder. Stimulus delivery was controlled
by the SR-LAB microcomputer and interface assembly,
which also digitized (0-4095), rectified, and recorded
stabilimeter readings. One hundred 1-ms readings were
collected beginning at stimulus onset. Startle amplitude was
defined as the average of the 100 readings.
Approximately 7 days after shipment arrival, rats were
exposed to a short “matching” startle session. They were
placed in the startle chambers for a 5-min acclimation
period with a 70-dB(A) background noise, and then
exposed to a total of 17 P-ALONE trails (40 ms–120 dB
(A) noise bursts) that were interspersed with 3 PP12dB + P-
ALONE trials (P-ALONE preceded 100 ms (onset-to-
onset) by a 20-ms noise burst of 12 dB above background).
Rats were assigned to dose order groups based on average
%PPI from the matching session to ensure similar baseline
PPI levels between groups. Four days later, rats were
injected with AMPH (0 or 4.5 mg/kg), and 10 min later
placed in the startle chambers for a 5-min acclimation
period with a 70-dB(A) background noise. They were then
exposed to a series of trial types identical to those used in
testing humans (see above, “Human testing”). One week
later, testing was repeated, with AMPH dose reversed.
Statistical analyses of startle magnitude and PPI were
structured identically to those used in humans, except that
strain was a between-subject grouping factor.
Results
Human testing
Three subjects were startle “non-responders” during testing;
two of these subjects were “non-responders” for both
placebo and AMPH weeks. Among the 17 remaining
subjects, autonomic and VAS measures provided evidence
that this dose of AMPH was “bioactive” at the time of PPI
testing: AMPH (20 mg) significantly increased resting heart
rate (F=5.39, df 1, 16, p<0.035), diastolic and systolic
blood pressure (F’s=11.23 and 8.99; p’s<0.005 and 0.009,
respectively), and reduced drowsiness (F=9.25, df 1, 16,
Fig. 1 Evidence of bioactivity of 20 mg AMPH in this study. a
AMPH prevented the drowsiness normally experienced by test
subjects. b AMPH also reduced blink rate, an effect likely linked to
a reduction in drowsiness. c AMPH also increased heart rate (BPM
beats per minute), and both diastolic and systolic blood pressure (DBP
and SBPP, respectively, in mm)
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p<0.008) and blink rate (F=5.83, df 1, 16, p<0.03; Fig. 1).
In contrast, this dose of AMPH had no significant effect on
perceived queasiness, dizziness, or sensory sensitivity (all
were arithmetically reduced by AMPH, but p’s were
>0.05).
There was no significant main effect of AMPH on PPI
(F<1), or significant interactions of AMPH dose × prepulse
interval (F<1). As planned, subjects were then divided
based on the lowest vs. highest 50% baseline PPI levels
(“low gaters” vs. “high gaters”). ANOVA revealed a
significant interaction between AMPH dose and baseline
PPI level (F=8.23, df 1, 15, p<0.012; Fig. 2). This was
true: (1) when the “orphan” median value was assigned to
either “low” or “high” groups, (2) when only extreme
terciles (ns=5 each) of the distribution were included, (3)
when “non-responders” were included or excluded from
analyses, and (4) when active pill order was included as a
grouping factor. Among “high gaters”, AMPH significantly
reduced PPI (F=17.75, df 1, 8, p<0.003); among “low
gaters”, PPI-enhancing effects did not reach significance
(F=2.17, df 1, 7, ns; d=0.35, 0.69, 0.79, 0.55, and 0.32 for
10, 20, 30, 60, and 120 ms prepulse intervals, respectively).
Regression analysis across all subjects revealed a highly
significant correlation between higher baseline PPI level
and greater PPI-reducing effects of AMPH (R=0.74,
p<0.0008).
Startle exhibited normal reflex habituation across the test
session (p<0.0001). AMPH had no significant effect on
startle magnitude (F=3.09, df 1, 16, ns; Fig. 2, inset) or
reflex habituation (F<1) across the test session. There were
also no differences in startle magnitude or habituation
across “low- vs. high-gating” subgroups or subgroup ×
AMPH interactions for these measures, and all statistical
outcomes, including correlations, remained unchanged
when the sample was paired so that the arithmetic impact
of AMPH on startle magnitude was ≪ 1% for both low- and
high-gating subgroups. Regression analyses revealed no
significant correlations between: (1) baseline PPI and startle
magnitude; (2) baseline PPI and the “AMPH effect” on
startle magnitude (mean startle after AMPH minus mean
startle after placebo), or (3) the “AMPH effect” on startle
and the “AMPH effect” on PPI (all p>0.05).
Plasma estradiol levels did not differ significantly
between AMPH test days and placebo test days (F<1),
were reliable (test 1 vs. test 2, R=0.55, p<0.025), and did
not correlate significantly with either baseline PPI levels
(R=0.04) or AMPH effects on PPI (R=0.23).
Analyses of personality correlates of physiological
measures were initially limited to test specific relationships
of AMPH effects on PPI to both novelty seeking (NS
subscale score) and sensation seeking (SSS total score),
based on previously published findings (Hutchison et al.
1999). It should be noted that these two scores were highly
correlated here (R=0.75, p<0.0007), as reported elsewhere
(Earleywine et al. 1992; Juckel et al. 1995). AMPH effects
on PPI correlated significantly with NS scores (higher NS
score associated with greater PPI-reducing effects of
AMPH, R=0.54, p<0.027) and SSS scores (higher total
SSS score associated with greater PPI-reducing effects of
AMPH, R=0.64, p<0.006), but did not correlate with other
TPQ scores or the EPQ Psychoticism or Extraversion
subscales. ANOVAs of PPI using median splits of these
scales revealed a significant interaction of AMPH × NS
(F=5.18, df 1, 17, p<0.04), and a similar trend for AMPH ×
SSS (F=3.29, df 1, 15, p<0.09); in each case, subjects in
the upper 50% of the scale exhibited PPI-reducing effects
of AMPH (F’s=21.38 and 6.69; p’s<0.003 and 0.04,
respectively), while those in the lower 50% tended to
exhibit PPI-enhancing effects of AMPH (Fig. 3). ANCO-
VAs of the “AMPH effect” (mean PPI after AMPH minus
mean PPI after placebo) using baseline PPI as the main
factor and NS or SSS scores as covariates in each case
revealed significant effects of baseline PPI (p<0.03 and p<
0.02, respectively) and personality scale (p<0.03 and p<
0.02, respectively), and no significant interaction of
Fig. 2 Effects of AMPH (“drug”) vs. placebo on PPI among
subgroups defined by median split of mean placebo PPI level. AMPH
significantly reduced PPI among “high-gating” subjects (p<0.003); in
“low-gating” subjects, PPI-enhancing effects of AMPH did not reach
significance, despite effect sizes between 0.55 and 0.79 for 20, 30, and
60 ms prepulse intervals. Regression analysis across all subjects
revealed a highly significant correlation between higher baseline PPI
level and greater PPI-reducing effects of AMPH (R=0.74, p<0.0008).
Inset shows no significant effect of AMPH on startle magnitude in
low- or high-gating subgroups
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baseline PPI and personality scale (both ns). Neither NS
nor SSS scores correlated significantly with basal PPI
levels (as previously reported (Swerdlow et al. 2003c)),
and “low gaters” and “high gaters” did not differ
significantly in either NS scores or SSS scores (F’s=2.36
and 2.05, respectively, both ns). In contrast, baseline PPI
levels were positively associated with reward dependence
(R=0.51, p<0.04) and tended to be associated with Harm
Avoidance (R=−0.48, p=0.052) subscales of the TPQ.
Based on these findings, we explored the relationships
Fig. 3 AMPH effects on PPI among subgroups based on median split
of personality scale scores. a ANOVA revealed significant PPI-
reducing effects of AMPH in subgroups characterized by high NS
scores (p<0.003). AMPH effects on PPI correlated significantly with
NS scores (higher NS score associated with greater PPI-reducing
effects of AMPH, R=0.54, p<0.027. Inset shows no significant effect
of AMPH on startle magnitude in low or high NS subgroups.
b Statistically comparable findings were detected using median split
analyses for SSS scores (significant PPI-reducing effects of AMPH in
the subgroup characterized by high SSS scores (p<0.04), and AMPH
effects on PPI correlated significantly with SSS scores (higher total
SSS scores associated with greater PPI-reducing effects of AMPH (R=
0.64, p<0.006)), and no significant effect of AMPH on startle
magnitude in low or high SSS subgroups)
Table 2 Personality scale scores vs. AMPH sensitivity
Scale Physiological effect of AMPH R p
NS Reduce PPI 0.54 <0.027a
NS Increase DBP 0.52 <0.035
NS Reduce blink rate 0.52 <0.035
RD Increase HR 0.63 <0.008
RD Increase “happy” VAS 0.56 <0.02
SSS Reduce PPI 0.64 <0.006a
a Confirms specific a priori hypotheses based on published reports
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between personality scale scores and laboratory indices of
AMPH sensitivity. Many suggestive correlations were
detected (Table 2), but none that would remain significant
after correcting alpha for multiple comparisons. While no
differences in AMPH effects on subjective assessments
were detected between individuals scoring low vs. high NS
or SSS scores, it is possible that neither the dose of AMPH
nor the choice of specific subjective scales were most
sensitive for detecting such group differences (Kelly et al.
2006).
Fig. 4 AMPH effects on PPI in female SD and LE rats, divided by
strain (a) and low vs. high baseline PPI levels (b). SD and LE rats
differ significantly in the expression of a number of DA-linked genes
in the nucleus accumbens; for example, expression of COMT mRNA
is significantly lower in SD vs. LE rats (p<10-17). a ANOVA
revealed significant PPI-reducing effects of AMPH in SD rats (p<
0.04), and PPI-increasing effects of AMPH in LE rats for the 20-ms
prepulse interval (p<0.03). Inset shows no significant effects of
AMPH on startle magnitude in SD or LE rats. b ANOVA revealed
significant PPI-reducing effects of AMPH in rats with high baseline
PPI (SD:LE=6:4; p<0.035), and PPI-increasing effects of AMPH in
low-gating rats for the 10–20-ms prepulse intervals (SD:LE=4:6; p<
0.05). Inset shows no significant effects of AMPH on startle
magnitude in low- or high-gating rats
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Rodent testing
ANOVA of PPI revealed no significant effect of strain (F<1)
or AMPH (F=1.29, df 1, 18, ns), but a significant interaction
of AMPH × strain (F=7.33, df 1, 18, p<0.015). There were
also significant effects of prepulse interval (F=33.79, df 4,
18, p<0.0001) and interactions of interval × strain (F=4.42,
df 4, 72, p<0.005) and interval × AMPH (F=5.75, df 4, 72,
p<0.0005; Fig. 4a). Separate ANOVAs in SD and LE rats
revealed significant PPI-reducing effects of AMPH in SD
rats (main effect of AMPH: F=5.92, df 1, 9, p<0.04;
AMPH × prepulse interval interaction ns), and significant
PPI-increasing effects of AMPH at the 20-ms prepulse
interval in LE rats (main effect of AMPH ns; AMPH ×
prepulse interval interaction: F=4.61, df 4, 36, p<0.005;
post hoc comparison limited to 20 ms interval: significant
effect of AMPH, p<0.03). AMPH had no significant
effects on startle magnitude in either rat strain (main effects
of strain, AMPH, and interaction all F<1).
Rats were then divided into “low gaters” vs. “high gaters”,
as had been done above for women, independent of rat strain.
ANOVA of PPI revealed a near significant effect of “low” vs.
“high” grouping (F=3.50, df 1, 18, p<0.08), no significant
effect of AMPH (F=1.27, df 1, 18, ns), and a significant
interaction of baseline PPI vs. AMPH (F=7.00, df 1, 18, p<
0.02; Fig. 4b). Separate ANOVAs in low- and high-gating rats
revealed significant PPI-reducing effects of AMPH in high-
gating rats (main effect of AMPH: F=6.44, df 1, 9, p<0.035;
AMPH × prepulse interval interaction ns), and significant
PPI-increasing effects of AMPH at the 10–20-ms prepulse
interval in low-gating rats (main effect of AMPH ns; AMPH
× prepulse interval interaction: F=4.78, df 4, 36, p<0.004;
post-hoc comparison limited to 10–20 ms intervals: signifi-
cant effect of AMPH, p<0.05). AMPH had no significant
effects on startle magnitude in either rat group (main effects
of baseline PPI, AMPH, and interaction all F<1).
Strain distributions across the low (SD:LE=4:6) and
high baseline PPI subgroups (SD:LE=6:4) were compara-
ble. Because strain (unlike personality scale score) is a
categorical variable and thus not informative as a covariate,
both strain and baseline PPI were included as grouping
factors in the ANOVA structure. The results revealed
significant interactions of AMPH × strain (p<0.03) and
AMPH × baseline PPI (p=0.03), and no significant
interaction of strain × baseline PPI × AMPH (F=1.42, df
4, 64, ns). In other words, strain and baseline PPI conferred
independent, significant effects on AMPH PPI sensitivity.
Discussion
AMPH has a rate-dependent effect on PPI in normal
women: the impact of AMPH on PPI is significantly
correlated with the amount (“rate”) or baseline PPI. One
might speculate that this pattern simply reflects a “regres-
sion to the mean”, perhaps based on physiological ceiling
or floor effects of PPI. However, PPI is a stable phenotype,
with test–retest reliability exceeding 0.8 under conditions
comparable to those tested here, for intervals ranging from
2 weeks to 1 year (Cadenhead et al. 1999; Swerdlow et al.
2001; Light et al. 2007); this would make it unlikely that
subjects would systematically alternate “low” vs. “high”
PPI status across tests. Furthermore, such an effect could
not be explained by a physiological “ceiling” in the present
data: “high” basal PPI in women is actually comparable to
“low” basal PPI in men using the current stimulus
parameters (Swerdlow et al. 2006), yet AMPH has opposite
effects on PPI in these two groups. Simple “range-
dependent” effect of AMPH on PPI also would not be
consistent with the current data from low vs. high NS
subjects. In this case, low vs. high NS groups do not differ
in basal PPI levels, and yet AMPH has opposite effects on
these groups, increasing PPI in low NS subjects, and
reducing PPI in high NS subjects.
Rate-dependent effects on PPI have been reported in
normal men with DA agonists (pergolide and amantadine;
Bitsios et al. 2005) and DA antagonists (quetiapine:
Swerdlow et al. 2006; haloperidol: Csomor et al. 2008;
clozapine: Vollenweider et al. 2006). As in the present
study, in some instances, these rate-dependent effects have
impacted both PPI and prepulse facilitation (“PPF”, i.e.,
“negative” PPI; e.g., Swerdlow et al. 2006). Thus, DAergic
drugs (including AMPH) appear to reduce the magnitude-
modulating impact of the prepulse on startle, whether this
impact is to reduce (PPI) or increase (PPF) startle
magnitude. Combined with the present AMPH data and
our past report of comparable effects of AMPH in normal
men (Swerdlow et al. 2003a), a consistent set of findings
has emerged that suggests that DAergic manipulations
modify prepulse effects on startle magnitude in normal
humans in a manner that depends on basal levels of PPI.
The observation that the effects of AMPH on PPI are
inversely related to baseline levels of PPI is not unique in
the literature of AMPH effects: a similar phenomenon of
“rate-dependent” drug action has been hypothesized to
underlie some of the therapeutic effects of stimulants in
attention deficit hyperactivity disorder (Lyon and Robbins
1975). Interestingly, an NIMH study (Fleming et al. 1995)
reported that after AMPH challenge, cognitive function
deteriorated in high NS subjects but improved in low NS
subjects, and concluded, “some cognitive abilities of
persons who may have relatively high DAergic tone are
disrupted by AMPH, while those with relatively low
DAergic tone may have their performance enhanced.” Such
“normalizing” effects of AMPH have been variously
ascribed to its action on opposing neural systems (e.g.,
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mesolimbic and nigrostriatal DA systems) or on DA
transmission supported by different DA receptor subtypes,
among other possible mechanisms.
The neural basis for these rate-dependent effects is not
known. PPI levels in normal humans may reflect, in part,
resting DAergic tone in the basal forebrain (cf. Swerdlow
et al. 2003c). Some evidence suggests that rat strains with
higher forebrain DA turnover and elevated COMT expres-
sion (e.g., LE rats) are most sensitive to the PPI-enhancing
effects of DA agonists, while strains with lower forebrain
DA turnover and COMT expression (e.g., SD rats) are most
sensitive to the PPI-disruptive effects of DA agonists
(Swerdlow et al. 2005; Shilling et al. 2008). This pattern
was reproduced in the present study. Conceivably, similar
neurochemical and genetic differences might distinguish
low- vs. high-“gating” humans. Some evidence supporting
such a mechanism is now emerging from studies of
neurocognitive and genetic characteristics of low- vs.
high-“gating” normals (Bitsios et al. 2006).
The notion that low vs. high levels of COMT activity
might impact sensitivity to the PPI-disruptive effects of DA
agonists might find support from the evidence that PPI
AMPH sensitivity appears to be linked to personality
measures of novelty seeking and sensation seeking, both
in the present cohort of women and in mixed-gender
samples (Hutchison et al. 1999). High novelty seeking in
women has been linked to Met/Met Val158Met COMT
polymorphism (Golimbet et al. 2007). Conceivably, low
COMT activity associated with this Met/Met polymorphism
and high NS scores might account for the predominant PPI-
reducing effects of AMPH in women, while low novelty
seeking linked to high COMT activity might account for
predominant PPI-enhancing effects of AMPH. This identi-
cal pattern of PPI AMPH sensitivity is observed in rat
strains with low vs. high COMT expression in the nucleus
accumbens (present study, Fig. 4; Shilling et al. 2008).
Such a mechanism might also account for the PPI-
enhancing effects of the DA antagonist, quetiapine, in
normal low-gating individuals with high novelty seeking
traits (Swerdlow et al. 2006). In this case, individuals with
high novelty seeking and low COMT activity may be
exhibiting low basal PPI levels due to high basal DA tone,
and these effects would be particularly sensitive to the PPI-
enhancing effects of DA receptor blockade. One important
caveat to the hypothesis that low COMT activity associated
with the Met/Met polymorphism accounts for the promi-
nent PPI-reducing effects of AMPH in high NS subjects is
that the link between high NS and the Met/Met polymor-
phism was detected in one study only in women (Golimbet
et al. 2007). Interestingly, in our previous report (Swerdlow
et al. 2003b), high NS was not associated with greater PPI
AMPH sensitivity in men (and in fact, the opposite pattern
was detected). We hope to directly test the relationship
between COMT polymorphisms, novelty seeking, and PPI
AMPH sensitivity in future studies in humans.
Importantly, these relationships between NS, baseline
PPI, and drug sensitivity were all detected in clinically
normal individuals and are all presumed to reflect processes
intrinsic to DAergic activity, up to the level of the post-
synaptic DA receptor (in the case of antipsychotic effects
on PPI). How these processes relate to PPI abnormalities in
pathological populations, which may reflect abnormalities
in cortical or subcortical systems “beyond” the DA neuron,
is not easily discerned from the present data.
A potential limitation of the present rodent studies is the
lack of hormonal measures: female rats were tested indepen-
dent of their estrous cycle phase. Koch (1998) reported that
PPI in female SD rats was reduced during proestrous
compared to diestrous or estrous, but that sensitivity to the
PPI-disruptive effects of a dopamine agonist did not vary
across the estrous cycle. We previously reported a pattern of
strain differences in PPI AMPH sensitivity among male SD
vs. LE rats comparable to those detected in the present study
with female rats (Swerdlow et al. 2003a), suggesting that the
present findings are not mediated by strain differences in
female reproductive hormones.
We do not know which DA receptor subtypes might be
responsible for the “rate-dependent” and perhaps COMT-
dependent effects of dopaminergic manipulations on PPI.
The drugs with which one or both of these effects have
been detected (amphetamine (Hutchison et al. 1999;
Swerdlow et al. 2003b and present data), amantadine and
pergolide (Bitsios et al. 2005) and several mixed D2-family
antagonists (Swerdlow et al. 2006; Vollenweider et al.
2006; Csomor et al. 2008) do not distinguish neatly among
D2, D3, or D4 receptors. We are currently testing the
relationship between basal PPI levels, novelty seeking, and
the effects of the D3-preferential agonist, pramipexole, on
PPI in normal men. Interestingly, the PPI-disruptive effects
of pramipexole do not differ between rat strains with low
vs. high accumbens COMT activity (Weber et al. 2008). If
our cross-species model is valid as it relates narrowly to the
role of COMT in the D3 regulation of PPI, we would
predict that—in contrast to AMPH—pramipexole effects on
PPI should not differ between individuals with low vs. high
novelty seeking traits.
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